

SUBJECT INDEX TO VOLUMES I AND II

A

Additive effect, I.55
Additive models, I.55, I.58, II.122–31
 choice between additive and multiplicative models, II.142–46
Age-incidence curves, II.55
Age-specific rates, II.49–51, II.193–95
Age-specific ratios, II.61, II.72
Age standardization, I.254
 of mortality rates, II.51–70
Age-standardized death rates, II.91
Age-standardized mortality ratios. *See* Standardized mortality ratios (SMRs)
Age/stratum-specific rates, II.61
Age-time specific comparisons, II.48
Alcohol consumption
 in relation to oesophageal cancer, I.216, I.218–20, I.223–24, I.227–35
 in relation to oral cancer, I.66, I.67, I.86, I.109, I.110
Alternative explanation of observed relationships, I.89
AMFIT program, II.175
Analysis of variance, multiplicative model for SMRs, II.158
Animal models, I.236
Ankylosing spondylitis, irradiation for, I.62
Annual incidence rates, I.43, I.47
Armitage–Doll model, II.256, II.264
 see also Multistage models of carcinogenesis
Asbestos exposure, I.21, I.90, II.31–34, II.38, II.103
 and lung cancer, II.242–44, II.262
 and mesothelioma, II.237–39, II.261

 combined with cigarette smoking, I.66–68, II.352–53

Association. *See* Disease association

Association strength, I.88–89

Asymptotic normality, II.133–35

Atomic bomb survivors, I.62, II.22

 life-span study, II.340–44

Attained significance level, I.128

Attributable risk, I.73–78, II.21

 for exposed persons, I.74

 population risk, I.74

 relative attributable risk, I.,76

B

Background rates

 incorporation into multiplicative model, II.151–53

 non-parametric estimation of, II.192–99

Bandwidth, choice of kernel estimates, II.193–95

Benzene exposure, risk of leukaemia, I.87

Benzidine exposure and bladder cancer, II.252

Benzo[*a*]pyrene, and incidence of skin tumours, I.237

Bermuda Case-Control Symposium, I.19

Bernoulli distribution, II.132

Biases, I.22, I.35, I.73, I.84–85, I.89, I.105, I.113, II.9, II.16, II.73

 arising from unconditional analysis of matched data, I.249–51

 due to errors of measurement, II.41–42
 see also Recall bias; Selection bias

Binomial coefficient, definition, I.125

Binomial distribution, definition, I.125

- Biological monitoring, II.20
 Birth cohort analysis, I.48
 Bladder cancer, II.21, II.30
 and benzidine exposure, II.252
 in chemical industry, II.11
 Bone tumours, and radiation exposure,
 II.249–50
 Boston Drug Surveillance Program, I.22,
 I.115
 Breast cancer, II.21
 age at first birth, I.64–66, I.77, I.86
 age-specific incidence rates, I.49, I.50,
 I.59, I.60, II.129
 and radiation exposure, II.247–49, II.262
 bilateral, I.87
 cohort analysis of Icelandic data, II.126–31
 comparison of indirect standardization and
 multiplicative model fitting, II.130
 example of negative confounding, I.93–94
 influence of reproductive factors, I.66
 irradiation-induced, I.62
 relative risks for, I.92
 reproductive experience in, I.17, I.66
 Breast disease, benign, II.187
 British doctors study, II.27, II.28, II.101,
 II.163–65, II.168–70, II.236,
 II.336–39
- C
- Calendar period-specific rates, II.49–51
 Calendar time, I.43
 Carcinogenesis, multistage models of,
 II.256–60
 Case-control sampling, II.205, II.289–302
 see also Risk set sampling
 Case-control studies
 applicability, I.21
 as related to cohort studies, II.3–22,
 II.35–36, II.42, II.44
 chi-squared test statistic
 1 D.F. test for trend, I.147–50
 combination of $2 \times K$ table, I.149
 goodness-of-fit, I.209–10
 in logistic regression, I.208–10
 goodness-of-fit, I.208, I.222, I.273
 matched pairs (McNemar test), I.165,
 I.184
 for homogeneity of relative risk,
 I.166–69, I.185
 1 D.F. test for trend, I.184
 matched samples ($1:M$), I.171, I.177
 for homogeneity and trend in relative
 risk, I.173–76
 series of 2×2 tables (Mantel–Haenszel
 statistic), I.138
 for homogeneity of relative risk,
 I.142, I.143
 for trend in relative risk, I.142
 series of $2 \times K$ tables, I.149
 trend test, I.149
 summary chi-squared for combination of
 2×2 table (Mantel–Haenszel
 statistic), I.138
 test of homogeneity, I.166–69
 2×2 table, I.131–32
 $2 \times K$ table, I.147
 contradictory results, I.19
 definition, I.14–16
 design considerations, II.272, II.289–302
 choice of case, I.23–25
 choice of control, I.25–28
 efficiency of, I.21
 future role of, I.18
 general considerations, I.14–40
 history, I.17
 limitations, I.22
 low cost of, I.21
 major strengths of, I.20–22
 objectives of, I.17, I.19–20
 planning, I.23–32
 present significance, I.17–19
 status of cases, I.24
 unmatched design considerations,
 II.289–94, II.302–4
- Causality, I.84–85
 criteria, I.36–37, I.86–90
 evidence of, I.90
- Chi-squared test statistic. *See* under Case-
 control studies; Cohort studies
- Childhood cancers, I.239–42
 Chronological age, I.43
 Cigarette smoking. *See* Tobacco
 consumption
- Classification errors, I.114
 Coding of disease, II.30
 Coffee drinking, lack of dose response for
 bladder cancer, I.86,

- Cohort studies
- chi-squared test statistic, II.68, II.94, II.137
 - comparison of two SMRs, II.94
 - for SMR, II.68, II.69
 - goodness-of-fit test for grouped data, II.129
 - heterogeneity of SMR, II.96
 - 1 d.f. test for trend of SMR, II.96
 - summary test for equality of relative risk, II.108, II.113
 - test for heterogeneity of relative risk, II.112
 - test for trend in relative risk, II.112
 - definition, II.2
 - design and execution, II.22
 - design considerations, II.271–88
 - further information from, II.28–29
 - general considerations, II.2–46
 - historical, II.2, II.5–11, II.19, II.21, II.32, II.33, II.35, II.37, II.42
 - identification of cancer cases, II.28
 - implementation, II.22–36
 - interpretation, II.36–45
 - limitations of, II.20–22
 - present significance of, II.11–20
 - problems in interpretation of, II.39–45
 - prospective, II.2, II.20, II.33, II.35, II.37
 - retrospective. *See* historical (*above*)
 - sample size for
 - comparison with external standard, 2.273–79
 - comparison with internal control group, 2.279–85
 - specific strengths of, 2.11–20
- Combined exposures, I.66–68
see also Joint effects
- Comparative mortality figure (CMF), II.48, II.61–63, II.90, II.125, II.126
- instability of, II.63
 - standard error of, II.64
 - versus SMR, II.72
- Comparison groups, choice of, II.33–34, II.39–40, II.61
- Comparisons with several disease or control groups, I.111–12
- Composite variables, I.105
- Computer programs, II.175, II.192, II.206
- AMFIT, II.175
 - GLIM. *See* GLIM
 - LOGODDS, I.322–38, II.189
 - MATCH, I.297–306
 - PECAN, II.206
- Conditional analysis, I.249
- Conditional distribution
- for 2×2 table, I.125
 - for series of 2×2 tables, I.138
- Conditional likelihood, I.204, I.209, I.248, I.251, I.253, I.255, I.270
- Conditional logistic regression analysis for matched sets, I.248–79, I.297–306
- Conditional maximum likelihood estimate for 2×2 table, I.127
- Confidence coefficient, definition, I.128
- Confidence intervals, I.134, I.165–67, I.182
- definition, I.128–29
 - for common odds ratio in series of 2×2 tables, I.141–42
 - for odds ratio in 2×2 table
 - Cornfield, I.133–34
 - exact, I.129
 - logit, I.134
 - test based, I.134
 - for ratio of SMR, II.95
 - for relative risk in matched pairs, I.163–67
 - for relative risk in matched sets (1:M), I.172–76, I.182
 - for the SMR, II.69–71
 - logistic regression parameters. *See* Covariance matrix of logistic regression parameters
 - test based, I.134, I.135
 - see also* Standard error of Mantel-Haenszel estimate
- Confounding, residual, I.100, I.101
- Confounding effects, I.84–85, I.93–108, II.87
- and misclassification, I.106
 - control of, I.29–30, I.36, I.111, I.136–56, I.162, I.166
 - effect of study design on, I.101–3
 - negative, I.95
 - of nuisance factors, I.225–26
 - on sample size requirements, II.304–6
 - statistical aspects of, I.94–97
 - see also* Logistic model and logistic regression; Standardized mortality ratios (SMRs), bias in the ratio of Stratification

Confounding risk ratio, I.76, I.96–97, I.99–101, II.33

Confounding score index, I.101

Conjugated oestrogen dose, I.178

Continuity correction, I.131–34, II.296, II.301

Continuous data, fitting models to II.178–229

Continuous data analysis, I.227–33
 choice of basic time variable, II.180–81
 comparison with grouped data analysis, II.211–12
 construction of exposure functions, II.181–82
 external standard rates, II.183–84
 fundamentals of, II.179–84
 in matched studies, I.265–68
 model equations, II.182–83
 of Montana smelter workers, II.206–18
 of South Wales nickel refiners – nasal sinus cancer, II.218–29

Continuous variables, I.92

Contour plot of deviances, II.169

Controls
 choice of control series, I.25–28
 selection procedure, II.205–6
see also Case-control studies; Matching; Risk set sampling

Cornfield's limits, I.133–34

Coronary disease among British male doctors, II.112, II.145, II.146

Corrected chi-squared statistic, I.131

Covariance matrix of logistic regression parameters, I.207

Cross-classification. *See* Stratification

Cross-sectional analysis of incidence rates, I.48

Cross-tabulation. *See* Stratification

Cumulative background rates, estimation of, II.192–97, II.204–5

Cumulative incidence rates, I.49–53

Cumulative rate, II.57–58
 standard error, II.58–61

Cumulative ratio, kernel estimation of, II.193–95

Cumulative relative rates, II.204–5

Cumulative standardized mortality ratio, II.207

D

Data acquisition, II.36

Data collection, II.35, II.42

Data points, influence of, II.139–40

Death rates, US national, II.358–61

Denominator information, II.26–28

Design considerations. *See* under Case-control studies; Cohort studies; Matching

Deviances
 contour plot of, II.169
see also Likelihood inference

Dichotomous exposure
 1:M matching, I.169–76
 in unmatched studies, I.124–46
 matched pairs, I.164–76
 variable number of controls, I.176–82

Dichotomous variables, I.91, I.94–97

Directly standardized rate, I.50, II.52–57, II.89–91
 standard error, II.58–61
see also Comparative mortality figure (CMF)

Disease association models, I.53–59

Disease occurrence, measures of, I.42–47

Dose metameter selection, II.98–99

Dose-response analysis, II.105, II.115–18
see also Logistic model and logistic regression; Regression analysis; Trend tests

Dose-response relationship, I.86, I.88, II.37, II.41, II.42, II.82, II.83, II.88, II.97, II.96, II.159, II.232
 multistage models, 2.262–63
see also Joint effects

Dose-time relationships, II.233–55

Dose-time-response relationships, II.120

Dose transformations, II.159

Dummy variables for logistic regression models, I.196, I.214

E

Ecological studies, II.4

Effect modification. *See* Interaction (modifying) effects

Efficiency calculations for matched designs,
II.302–4

Empirical odds ratio, I.127

Endometrial cancer, I.24, I.29, I.90, I.104,
I.265

Los Angeles study of, I.162–63, I.185,
I.253, I.255, I.258, I.260, I.261,
I.263, I.264, I.266, I.290–96

Endometrial hyperplasia, I.30

Epithelial tumours, age-specific rates and
latent period, I.60, I.62, I.89

Errors of classification and of measurement,
I.114, II.41–42, II.265–66
generating confounding, I.106

Estimation of odds ratio

combination of 2×2 table

logit estimate, I.139

Mantel-Haenszel estimate, I.140, I.141

maximum likelihood estimate, I.140

2×2 table

asymptotic maximum likelihood, I.130

exact conditional maximum likelihood,
I.124

see also Logistic regression

Excess mortality ratio (EMR), II.174, II.175,
II.268

Excess risk, I.55, I.58, I.64, I.84, II.45

Excess risk model

fitting to grouped data, II.171–76

see also Additive models

Exponential distribution, II.132

Exponential survival times, II.131–32

Exposure functions, II.181–82

Exposure index, II.172–73

Exposure information, II.30–33, II.37

Exposure probability, I.71

Exposure variables, lagging of, II.48, II.87

External standard rates, II.212–14

Extra Poisson variability, II.99–100

F

Familial risk, I.87

Fisher's exact test, I.128, I.129, I.133

Fitted values in 2×2 table, I.130

Follow-up losses, II.40–41, II.49

Follow-up mechanisms, II.17, II.25–29

Follow-up period, II.288–89

Follow-up schema, II.50

Force of morbidity, I.45

Force of mortality, I.45

Forerunners of disease, II.44

G

Gall-bladder disease, I.22, I.168, I.254–59,
I.262, I.264, I.265

Gastric cancer, age-specific incidence rates,
I.62

GLIM computer program, I.206, I.208,
I.214, I.253, II.128, II.136–37,
II.139, II.141–143, II.160, II.162,
II.163, II.167, II.174, II.175

Global statistic for homogeneity test, I.142

Global test, I.153

Goodness-of-fit, I.142, II.161, II.190, II.199
analysis of residuals, II.138–39, II.144–46
in logistic regression, I.208, I.222, I.273
influential data points, II.139–40,
II.144–46

multiplicative models, II.148, II.149

statistics, II.141, II.144

summary of measures of, II.137–38

see also Case-control studies, chi-squared
test statistic; Cohort studies, chi-
squared test statistic

Greenwood's formula, II.192

Group-matching, I.122

Grouped data, fitting models to, II.120–76

Grouped data analysis

case-control studies, I.122–59

goodness-of-fit in logistic regression,
I.208, I.222, I.273

Ille-et-Vilaine study of oesophageal
cancer, I.281–83

Oxford Childhood Cancer Survey,
I.284–89

qualitative analysis of, I.213–19

quantitative analysis of, I.221–24

cohort studies, II.106–15

comparison with continuous data
analysis, II.211–12

conservatism of indirect standardization,
II.114–15

extensions to $K > 2$ exposure classes,
II.113–114

- Grouped data analysis—contd.
 cohort studies—contd.
 heterogeneity of relative risk, II.110–13
 Mantel-Haenszel estimate, II.109–13
 Montana cohort, II.146–50, II.155–59
 restrictions on, II.178
 summary test of significance, II.108
 two dose levels, exposed versus unexposed, II.107–8
 maximum likelihood estimate, II.108–13
- H
- Hat matrix in residual analysis, II.138–40
 Hazard rate, I.45
 Hazards, proportional, I.201
 Healthy worker effect, II.17, II.39–40, II.87, II.98
 Heterogeneity, II.75–76
 see also Case-control studies, chi-squared test statistic; Cohort studies, chi-squared statistic
 Historical cohort studies, II.2, II.19
 HLA antigen A2 and leukaemia, association with survival, I.25
 HLA antigens and multiple comparison, I.115
 Hodgkin's disease and tonsillectomy, I.16, I.31
- Homogeneity of relative risk
 in matched pairs, I.166–67
 in matched sets (1:M), I.173–74
 in series of 2×2 tables, I.137, I.142–43
 tests for homogeneity, *see under* Case-control studies; Cohort studies
 Homogeneity test, global statistic for, I.142
 Hypergeometric distribution
 central, definition, I.127
 K-dimensional, I.147
 non-central, definition, I.127
 Hypertension, I.168, I.169, I.254–59
- I
- Ille-et-Vilaine study of oesophageal cancer, I.122–24, I.162, I.210, I.213–33, I.238, I.281–83
 Implementation
 in case-control studies, I.32–35
 in cohort studies, II.22–36
 Incidence cohorts, II.25
 Incidence rates, I.43, I.66, I.71
 age-specific, I.44, I.47–48, I.59–61
 calculation of, I.44
 cumulative, I.49–53
 directly standardized, I.50
 estimation of, I.45
 logarithmic transformation of, I.57
 overall, I.76
 time-specific, I.47–48
 variations in, I.55
 Indicator variables. *See* Dummy variables
 Indirect standardization, II.48
 see also Standardized mortality ratios (SMRs)
 Influence of individual data points, II.139–40, II.144–46
 Information matrix, I.207
 Initial treatment of data, I.90–93
 Instantaneous rate, I.45
 Insulation workers, 2.103
 Interaction (modifying) effects, I.108–11, I.167, II.110–13
 definition of, I.108–11
 effect on sample size requirement and matching, II.308–10
 in conditional logit analysis, I.262–68, I.273
 in logistic model
 definition of, I.196–200
 test for, I.221–24
 in series of 2×2 tables, I.238–42
 negative, I.196
 see also Case-control studies; Cohort studies
 Interaction parameter
 in logistic regression, I.196
 Internally standardized mortality ratios, II.103–6
 International Classification of Diseases (ICD), II.30, II.355–57
 Interpretation, basic considerations, I.35–37, I.112–15
 Interviews, I.33–34
 questionnaires, I.34
 Iran, oesophageal cancer in Caspian littoral of, I.275, I.276
 Irradiation
 obstetric, and associated cancer risk,

I.239–42
 risk of cancer following, I.62–63
 Ischaemic heart disease, and cigarette
 smoking, I.68

J

Joint distribution, I.99
 Joint effects of multiple exposures, I.66–68,
 I.99, I.111, I.154–56, I.227,
 II.266–67
see also Interaction (modifying) effects

K

Kernaël estimation of cumulative ratio,
 II.193–95

L

Lagging of exposure variables, II.48, II.87
 Large strata, unconditional logistic
 regression for, I.192–246
 Latency function, II.181–82, II.216–17,
 II.264–66
 Latent period, I.89
 Least-squares analyses, II.161
 Least-squares linear regression analysis,
 II.99–103
 Leukaemia, and radiation exposure,
 II.244–47
 Likelihood inference: outline of I.205–10
 likelihood ratio statistic, I.209
 likelihood ratio test, I.207
 log-likelihood analysis, I.206
 log-likelihood function, I.206, II.134,
 II.184–92, II.202–3
see also Partial likelihood
 log-likelihood statistic, I.206
 log-normal distribution, II.181
 Log-linear models, definition, I.57
 Log odds. *See* Logit transform
 Log relative risks as logistic regression
 parameters, I.196
 Logistic model and logistic regression, I.142
 case-control studies, I.202–5
 general definition of, I.200–2

introduction to, I.193–200
 results of fitting several versions of, I.212
 Logistic regression model, II.153–54
 dummy variable for, I.196, I.214
 Logit confidence limits from combination of
 2 × 2 tables, I.134
 Logit estimate, I.139
 Logit limits, I.141
 Logit transform, I.194, I.196
 LOGODDS program listing, I.322–38,
 II.189
 Longitudinal studies, II.2
 Los Angeles study of endometrial cancer,
 I.162–63, I.185, I.253, I.255, I.258,
 I.260, I.261, I.263, I.264, I.266,
 I.290–96
 Losses to follow-up, II.40–41, II.49
 Lost-to-follow-up subjects, II.49
 Lung cancer, II.38, II.39, II.43, II.100,
 II.103
 age- and year-specific death rates,
 II.391–94
 and asbestos exposure, II.242–44, II.262
 and uranium miners, II.253–55
 British male doctors, II.163–65, II.168,
 II.169, II.170
 in relation to tobacco consumption, I.17,
 I.55, I.58, I.64, I.66–69, I.75,
 I.86–93, I.100, I.101, I.104, I.166,
 I.193, II.5–9, II.15, II.234–36,
 II.261
 combined with asbestos exposure,
 I.66–68
 relative risk of, II.235
 South Wales nickel refiners, II.171, II.174,
 II.268, II.347–48

M

McNemar's test, I.165
 Mantel test for trend, I.148
 Mantel-Haenszel analysis, II.82
 estimate for cohort studies, II.109–113,
 II.147, II.285
 for case-control studies, I.138–42, I.144,
 I.165, I.171, I.172, I.174, I.177,
 I.179, I.181, I.192, I.195–96
 test for cohort studies, II.189
 Mantel-Haenszel statistic, I.138
 MATCH program listing, I.297–306

- Matched case-control studies, II.297
 design
 comparison with unmatched design, II.306
 number of controls per case, II.304
 sample size requirements for
 dichotomous exposure, II.294–302
- Matched data analysis, I.162–89
 conditional logistic regression analysis for, I.248–79, I.297–306
 conditional logistic regression, I.248–79, I.297–306
 dichotomous variables
 1:1 matching, I.164–69
 1:M matching, I.169–76
 variable number of controls, I.176–82
 polytomous variables, I.182–87
- Matched designs, efficiency calculations for, I.270–76, II.302–4
- Matched versus unmatched analyses, I.102–6, I.249–51, I.270–76
- Matching
 by strata, I.30–31
 in choice of controls, I.28–32
 problems associated with, I.31
- Maximum likelihood estimate (MLE). *See* Estimation of odds ratio; Likelihood inference
- Mesothelioma
 and asbestos exposure, II.237–39, II.261
 of the pleura, I.21
- Misclassification, I.114
see also Biases; Errors of classification and of measurement
- Misclassification rates, II.42
see also Biases, due to errors of measurement
- Missing data, I.113–14
- Model selection, II.203–4
 biological basis for, II.125
- Modelling risk, I.111
- Models, disease association, I.53–59
- Modifying effect. *See* Interaction
- Montana smelter workers
 cohort studies, II.18, II.23, II.32, II.37, II.52, II.53, II.60, II.78, II.79, II.86–99, II.105, II.114, II.148, II.149, II.152, II.154, II.206–18, II.232, II.349–50
 grouped data analyses, II.146–50, II.155–59, II.363–65
 multiplicative models, II.146–50, II.211, II.213,
 numbers alive and under observation, II.202
 regression analyses, II.157–59
 respiratory cancer, II.157, II.158
- Mortality, proportional, II.45–46, II.76, II.115–18
- Mortality rates, I.43
 age-specific, I.65
 age standardization of, II.51–70
 estimation of, I.45
- Mortality ratios, standardized. *See* Standardized mortality ratios
- Mouth cancer. *See* Oral cancer
- Multiple comparison, I.115, II.43–44
- Multiple exposure levels, I.189
 matched studies, I.146–54, I.182–87
see also Logistic model and logistic regression
- Multiplicative models, I.57, I.58, I.67, II.122–31, II.135–42
 choice between additive and multiplicative models, II.142–46
 comparison with indirect standardization, II.125–31
 estimating base line rates under, II.195–99
 fitting of, II.148
 general form of, II.136
 goodness-of-fit, II.148, II.149
 incorporating external standard rates, II.151–53
- Montana smelter workers, II.146–50, II.211, II.213
- nasal sinus cancer in South Wales nickel workers, II.223, II.224, II.226, II.227
- partial likelihood for, II.185–86
 regression coefficients, II.158
- Multistage models of carcinogenesis, II.256–60
 dose-response relationship, II.262–63
 interpretation of epidemiological data in terms of, II.261–62
 metameters of dose when dose levels vary, II.263–65
 Welsh nickel refinery data, II.267–70

Multivariate analysis. *See* Logistic model and logistic regression

Multivariate normality, I.204

N

Nasal sinus cancer in South Wales nickel refinery workers, II.105, II.106, II.142, II.172, II.218–29, II.268, II.367, II.369–74

age- and year-specific death rates, II.391–94

fitting relative and excess risk models to grouped data, II.171–76

multiplicative model, II.223, II.224, II.226, II.227

see also Continuous data analysis

Negative confounding, I.95

Negative interaction, I.196

Negative results, II.44–45

Nested hierarchy of models, I.207

Nickel workers. *See* South Wales nickel refiners

Non-central hypergeometric distribution, definition, I.127

Non-identifiability problem, II.128

Non-multiplicative models and partial likelihood, II.191

Non-oestrogen drug use, I.262, I.264, I.265

Non-parametric estimation

background rates, II.192–99

relative mortality functions, II.197–99

Normal approximation to exact distribution for 2×2 table, I.129

Nuisance factors, confounding effects of, I.225–26

Nuisance parameters, I.205

O

Obesity and risk of endometrial cancer, I.262, I.265

Obstetric radiation and associated risk of cancer, I.239–42

Odds ratio, I.70, I.73, I.94–96, I.99, I.102, I.103, I.106, I.108, I.130–31, I.135, I.139, I.140, I.196, I.250–10, I.241, I.252

empirical, I.172

equivalence to relative risk, I.70–72
estimation of. *See* Estimation of odds ratio

test for consistency, I.185–87

test for homogeneity, I.142–46, I.167

Oesophageal cancer, II.36, II.45, II.159

among Singapore Chinese, I.274

dose-response, II.263

Ille-et-Vilaine study of, I.222–24, I.162, I.210, I.213–33, I.238, I.281–83

in Caspian littoral of Iran, I.275, I.276

in relation to alcohol consumption, I.216, I.218–20, I.223–24, I.227–35

in relation to tobacco consumption, I.154, I.155, I.217–19, I.221, I.223–24, I.227–35, II.266

log relative risk, I.216, I.217, I.220, I.221

Oestrogen use, I.24, I.29, I.90, I.93, I.104, I.254–59, I.262, I.264, I.265

Oral cancer in relation to alcohol and tobacco consumption, I.66, I.67, I.86, I.109, I.110

Oral contraceptives, I.22

Overmatching, I.104–6

Oxford Childhood Cancer Survey, I.239–42, I.270, I.284–89, I.322

P

p-values as measure of degree of evidence, I.128

Partial likelihood, II.186, II.188, II.189
for multiplicative models, II.185–86

Partial likelihood analysis, II.200, II.212–14, II.212

PECAN program, II.206

Person-years, algorithm for exact calculation, II.362

Person-years allocation, II.49–51, II.83, II.85–86, II.88

to time-dependent exposure categories, II.82–86

Point prevalence, I.42

Poisson distribution, II.68, II.69, II.70, II.274

Poisson models

and the Poisson assumption, II.131–35
for grouped data, II.185

Poisson rates, fitting general models to, II.160–67

- Poisson variability, II.99, II.100
 Poolability of data. *See* Matched data analysis
 Population attributable risk, I.74, II.21
 Population controls, I.276
 Portsmouth (USA) Naval Shipyard workers, II.99
 Positive confounding, I.95, I.101
 Positive interaction, I.196
 Potential confounding, I.107
 Power considerations, II.34–35
 see also Case-control studies, design considerations; Cohort studies, design considerations
 Power to detect interaction, II.308–10
 Prevalence, point, I.42
 Prevalence cohorts, II.25
 Proportional hazards, I.201
 Proportional mortality, II.45–46, II.76, II.115–18
 analysis II.153–55, II.216
 incorporating standard rates, II.154–55
 risk functions for, II.168–71
 Proportionality assumption, II.93
 Prospective cohort studies, II.2
- Q**
- Questionnaires, I.34
 information management, I.34–35
- R**
- Radiation exposure
 and bone tumours, II.249–50
 and breast cancer, II.247–49, II.262
 and cigarette smoking, II.254
 and leukaemia, II.244–47
 Rate of occurrence, I.43
 Rates and rate standardization, II.48–79
 cumulative rate, II.57–58
 directly standardized rate, II.52–57
 standard error of cumulative or directly standardized rate, II.58–61
 standardized to world population, II.55–57
 summary measures, II.51
 see also Incidence rates; Mortality rate; Standardized mortality ratios (SMRs)
 Recall bias, I.22, I.35, I.84–85, I.113, II.16
 Regression adjustment for confounders, I.225–26
 Regression analysis, I.232, II.91, II.99, II.100
 Montana smelter workers, II.157–59
 see also Logistic model and logistic regression
 Regression coefficients, I.197, I.215, I.218, I.224, I.274, II.140, II.142
 interpretation of, I.233–36
 multiplicative model, II.158
 standardized, I.208
 Regression diagnostics, II.138–42, II.146, II.161, II.203–4
 Regression models, I.214, I.215, I.222, I.240
 Regression variables, I.239, I.254–59
 Relative attributable risk (RAR), I.76
 Relative mortality functions, nonparametric estimation, II.197–99
 Relative mortality index (RMI), II.75
 Relative risk, I.57–67, I.69–73, I.77, I.84, I.87–89, I.110, I.113, II.106–14, II.142
 additive, II.160
 see also Odds ratio
 Relative risk estimation, II.94–95, II.108–10, II.147
 general models of, II.159–71
 incorporating external standard rates, II.167
 see also Estimation of odds ratio; Mantel-Haenszel analysis
 Relative standardized mortality ratio (RSMR), II.77–78
 Reproductive factors in breast cancer, I.66
 Residual analysis, Hat matrix in, II.138–40
 Residual confounding, I.100, I.101
 Residuals, standardized, I.213
 Respiratory cancer, II.60, II.105, II.207
 standard death rates, II.88
 standard proportion of deaths due to, II.155
 Retirement, II.27
 Risk, I.51, I.53
 see also Excess risk; Relative risk
 Risk-dose-time relationship, modelling, II.232–70
 Risk factors, I.25, I.53, I.55, I.56, I.58, I.66, I.76, I.123, I.128
 binary, I.263

constellation of, I.199
 joint effects of, I.154–56
 more than two levels, I.198
 Risk ratio. *See* Relative risk; Odds ratio
 Risk set sampling, II.199–206, II.214–16,
 II.302–4
 Risk specificity
 disease subgroups, I.86–87
 exposure subcategories, I.87
 Risk variables, I.123
 transforming continuous, I.236–38
 Rule of 5, I.139

S

Sample size. *See* Case-control studies, design
 considerations; Cohort studies,
 design considerations; Confounding
 effects; Interaction; Matching
 Sampling requirements, I.72
 Score statistic, I.207
 Second order interaction, I.199
 Selection bias, I.22, I.35, I.85, I.89, I.113,
 II.17, II.49
 Serial measurements, II.20
 Significance level
 attained, I.218
 two-sided, I.133
 Significance tests, I.127, I.131–33
 Single-tail test, I.133
 Skin cancer, case-control study of, I.200
 Skin tumours, I.236
 estimated cumulative incidence rates, I.237
 in mice, I.46, I.53, I.54
 South Wales nickel refiners, II.23–25, II.32,
 II.37, II.142, II.143, II.218–29,
 II.233
 continuous data II.374–90
 lung cancer in II.171, II.174, II.268,
 II.347–48
 mortality experiences, II.171
 multistage models, II.267–70
 nasal sinus cancer, II.268, II.365–67,
 II.369–74
 Spurious associations, I.89
 Standard error
 of CMF, 2.64
 of Mantel-Haenszel estimate, II.109
 of SMR, II.67

Standard populations, II.54–55
 Standardized mortality ratios (SMRs), II.49,
 II.65–68, II.83, II.88, II.125, II.126,
 II.128, II.151, II.152, II.157, II.158,
 II.173, II.175, II.197–98, II.268
 advantages over CMF, II.65–66
 approximate limits for, II.70
 bias in the ratio of, II.72–75, II.92
 by years since first employed, II.217–18
 comparison of II.91–103
 confidence intervals for, II.69–72
 testing for heterogeneity and trend in,
 II.96–97
 testing significance of, II.68–69
 versus CMF, II.72
 Standardized regression coefficient, I.208
 Standardized residuals, I.213
 Statistical inference, I.124–29, I.206
 approximate methods of, I.129
 see also Likelihood inference
 Statistical interaction, definition, I.56
 Statistical modelling, advantages and
 limitations of, II.120
 Stomach cancer, age-specific incidence rates,
 I.60, I.61
 STRAT program listing, I.307–21
 Strata matching, I.30–31
 Stratification, I.89, I.105, I.111, I.122, I.225,
 I.242
 see also Confounding, control of
 Stratification degree, I.99–101
 Summary chi-squared test for combination of
 2 × 2 tables. *See* under Case-control
 studies; Cohort studies
 Summary measures
 of goodness-of-fit, II.137–38
 of rates, II.51–61
 Survival rates, I.43
 Survival times, II.131–32

T

Tail probabilities, I.27
 Time-dependent exposure categories,
 person-years allocation to, II.82–86
 Time on study, I.43
 Time relationships, II.37–39
 Tobacco consumption, II.43, II.46, II.88,
 II.101, II.103

Tobacco consumption—contd.
 and mortality, II.6
 and radiation exposure, II.254
 in relation to lung cancer, I.17, I.55, I.58,
 I.64, I.66–69, I.75, I.86–93, I.100,
 I.101, I.104, I.166, I.193, II.5–9,
 II.15, II.234–36, II.261
 combined with asbestos exposure,
 I.66–68, II.352–53
 in relation to oesophageal cancer, I.154,
 I.155, I.217–19, I.221, I.223–24,
 I.227–35, II.266
 in relation to oral cancer, I.66–69, I.86,
 I.110

Tonsillectomy and Hodgkin's disease, I.16,
 I.31

Trend tests
 for exposure effect versus trend test for
 dose-response, II.97–98
see also under Case-control studies,
 chi-squared test statistic; Cohort
 studies, chi-squared test statistic

2×2 table, I.126, I.146, I.148, I.154, I.169
 approximate statistical inference for,
 I.129–44
 combining results from, I.136–56,
 I.210–13
 combining sets of, I.268–70
 conditional distribution for, I.125, I.138
 conditional maximum likelihood estimate
 for, I.127
 equivalence of odds ratio and relative risk,
 I.70–72
 exact statistical inference, I.124–29
 interaction in, I.238–42
 odds ratio in, I.248

$2 \times K$ table, I.146–54

Two-sided significance level, I.133

Two-sided test, I.128

U

Unconditional analysis of matched data, bias
 arising from, I.249–51

Unconditional likelihood for logistic
 regression, I.209, I.253

Unconditional likelihood function, I.269

Unconditional logistic regression, I.269
 for large strata, I.192–46

Unconditional model, I.269

Unknown parameters, I.125

Unmatched analysis, I.271–76

Unmatched case-control studies, design
 considerations, II.289–94, II.302–4

Unstratified analysis, I.146–47

Uranium miners, and lung cancer, II.253–55

Urinary tract tumour, I.52, I.86

US national death rates, II.358–61

Uterine bleeding, I.104

Uterine cancer, I.27

V

Vaginal adenocarcinoma, I.89

W

Weighted least squares regression, I.60

Welsh nickel refiners. *See* South Wales nickel
 refiners

Wolf estimate. *See* Logit estimate

Y

Yates correction. *See* Continuity correction